Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in $\small \textit{BRCA1}$ and $\small \textit{BRCA2}$ Mutation Carriers
Authors
Kuchenbaecker, Karoline B
Beesley, Jonathan
Adlard, Julian
Agnarsson, Bjarni A
Andrulis, Irene L
Arun, Banu K
Barjhoux, Laure
Belotti, Muriel
Benitez, Javier
Berger, Andreas
Bojesen, Anders
Bonanni, Bernardo
Brewer, Carole
Caldes, Trinidad
Caligo, Maria A
Campbell, Ian
Chan, Salina B
Claes, Kathleen BM
Cohn, David E
Cook, Jackie
Daly, Mary B
Damiola, Francesca
Davidson, Rosemarie
Pauw, Antoine de
Delnatte, Capucine
Diez, Orland
Domchek, Susan M
Dumont, Martine
Durda, Katarzyna
Dworniczak, Bernd
Eccles, Diana
Edwinsdotter, Ardnor Christina
Eeles, Ros
Ejlertsen, Bent
Ellis, Stephen David
Evans, D Gareth
Feliubadalo, Lidia
Fostira, Florentia
Foulkes, William D
Friedman, Eitan
Frost, Debra
Gaddam, Pragna
Ganz, Patricia A
Garber, Judy
Garcia-Barberan, Vanesa
Gauthier-Villars, Marion
Gehrig, Andrea
Gerdes, Anne-Marie
Giraud, Sophie
Godwin, Andrew K
Goldgar, David E
Hake, Christopher R
Hansen, Thomas VO
Healey, Sue
Hodgson, Shirley
Hogervorst, Frans BL
Houdayer, Claude
Hulick, Peter J
Imyanitov, Evgeny N
Isaacs, Claudine
Izatt, Louise
Izquierdo, Angel
Jacobs, Lauren
Jakubowska, Anna
Janavicius, Ramunas
Jaworska-Bieniek, Katarzyna
Jensen, Uffe Birk
John, Esther M
Vijai, Joseph
Karlan, Beth Y
Kast, Karin
Investigators, KConFab
Khan, Sofia
Kwong, Ava
Laitman, Yael
Lester, Jenny
Lesueur, Fabienne
Liljegren, Annelie
Lubinski, Jan
Mai, Phuong L
Manoukian, Siranoush
Mazoyer, Sylvie
Meindl, Alfons
Mensenkamp, Arjen R
Montagna, Marco
Nathanson, Katherine L
Neuhausen, Susan L
Nevanlinna, Heli
Niederacher, Dieter
Olah, Edith
Olopade, Olufunmilayo I
Ong, Kai-ren
Osorio, Ana
Park, Sue Kyung
Paulsson-Karlsson, Ylva
Pedersen, Inge Sokilde
Peissel, Bernard
Peterlongo, Paolo
Pfeiler, Georg
Phelan, Catherine M
Piedmonte, Marion
Poppe, Bruce
Pujana, Miquel Angel
Radice, Paolo
Rennert, Gad
Rodriguez, Gustavo C
Rookus, Matti A
Ross, Eric A
Schmutzler, Rita Katharina
Simard, Jacques
Singer, Christian F
Slavin, Thomas P
Soucy, Penny
Southey, Melissa
Steinemann, Doris
Stoppa-Lyonnet, Dominique
Sukiennicki, Grzegorz
Sutter, Christian
Szabo, Csilla I
Tea, Muy-Kheng
Teixeira, Manuel R
Teo, Soo-Hwang
Terry, Mary Beth
Thomassen, Mads
Tibiletti, Maria Grazia
Tihomirova, Laima
Tognazzo, Silvia
van, Rensburg Elizabeth J
Varesco, Liliana
Varon-Mateeva, Raymonda
Vratimos, Athanassios
Weitzel, Jeffrey N
McGuffog, Lesley
Kirk, Judy
Toland, Amanda Ewart
Hamann, Ute
Lindor, Noralane
Ramus, Susan J
Greene, Mark H
Couch, Fergus J
Offit, Kenneth
Chenevix-Trench, Georgia
Publication Date
2016-07-27Journal Title
PLoS ONE
Publisher
Public Library of Science
Volume
11
Number
e0158801
Language
English
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Vigorito, E., Kuchenbaecker, K. B., Beesley, J., Adlard, J., Agnarsson, B. A., Andrulis, I. L., Arun, B. K., et al. (2016). Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in $\small \textit{BRCA1}$ and $\small \textit{BRCA2}$ Mutation Carriers. PLoS ONE, 11 (e0158801)https://doi.org/10.1371/journal.pone.0158801
Abstract
Population-based genome wide association studies have identified a locus at 9p22.2 associated with ovarian cancer risk, which also modifies ovarian cancer risk in $\small \textit{BRCA1}$ and $\small \textit{BRCA2}$ mutation carriers. We conducted fine-scale mapping at 9p22.2 to identify potential causal variants in $\small \textit{BRCA1}$ and $\small \textit{BRCA2}$ mutation carriers. Genotype data were available for 15,252 (2,462 ovarian cancer cases) $\small \textit{BRCA1}$ and 8,211 (631 ovarian cancer cases) $\small \textit{BRCA2}$ mutation carriers. Following genotype imputation, ovarian cancer associations were assessed for 4,873 and 5,020 SNPs in $\small \textit{BRCA1}$ and $\small \textit{BRCA2}$ mutation carriers respectively, within a retrospective cohort analytical framework. In $\small \textit{BRCA1}$ mutation carriers one set of eight correlated candidate causal variants for ovarian cancer risk modification was identified (top SNP rs10124837, HR: 0.73, 95%CI: 0.68 to 0.79, p-value 2× 10−16). These variants were located up to 20 kb upstream of $\small \textit{BNC2}$. In $\small \textit{BRCA2}$ mutation carriers one region, up to 45 kb upstream of $\small \textit{BNC2}$, and containing 100 correlated SNPs was identified as candidate causal (top SNP rs62543585, HR: 0.69, 95%CI: 0.59 to 0.80, p-value 1.0 × 10−6). The candidate causal in $\small \textit{BRCA1}$ mutation carriers did not include the strongest associated variant at this locus in the general population. In sum, we identified a set of candidate causal variants in a region that encompasses the $\small \textit{BNC2}$ transcription start site. The ovarian cancer association at 9p22.2 may be mediated by different variants in $\small \textit{BRCA1}$ mutation carriers and in the general population. Thus, potentially different mechanisms may underlie ovarian cancer risk for mutation carriers and the general population.
Keywords
ovarian cancer, mutation, genome-wide association studies, meta-analysis, cancer genomics, variant genotypes, cancer detection and diagnosis, alleles
Sponsorship
Cancer Research UK (Grant IDs: C12292/A11174, C1287/A10118), Medical Research Council (Advanced Studentship award)
Embargo Lift Date
2100-01-01
Identifiers
External DOI: https://doi.org/10.1371/journal.pone.0158801
This record's URL: https://www.repository.cam.ac.uk/handle/1810/257253
Recommended or similar items
The following licence files are associated with this item: